[1] |
中华医学会内分泌学分会《中国甲状腺疾病诊治指南》编写组. 中国甲状腺疾病诊治指南——甲状腺功能亢进症[J]. 中华内科杂志, 2007, 46(10):876-882.
|
[2] |
李晓辉, 尹洁, 洪旭. 促甲状腺激素受体抗体在Graves病诊治中的应用进展[J]. 北京医学, 2020, 42(2):136-138.
|
[3] |
中华医学会, 中华医学会杂志社, 中华医学会全科医学分会, 等. 甲状腺功能亢进症基层诊疗指南(实践版·2019)[J]. 中华全科医师杂志, 2019, 18(12):1129-1135.
|
[4] |
KAHALY G J, BARTALENA L, HEGEDÜS L, et al. 2018 European Thyroid Association Guideline for the management of graves' hyperthyroidism[J]. Eur Thyroid J, 2018, 7(4):167-186.
DOI
URL
|
[5] |
LUONG J H T, MALE K B, GLENNON J D. Biotin interference in immunoassays based on biotin-strept(avidin) chemistry:an emerging threat[J]. Biotechnol Adv, 2019, 37(5):634-641.
DOI
URL
|
[6] |
张国峰, 郭锐, 关海霞. 重视化验单之外的信息——由生物素干扰检验而被误诊为Graves病甲状腺功能亢进症的实例谈诊断甲状腺疾病的要素[J]. 中华内分泌代谢杂志, 2017, 33(9):723-725.
|
[7] |
ALLELEIN S, EHLERS M, GORETZKI S, et al. Clinical evaluation of the first automated assay for the detection of stimulating TSH receptor autoantibodies[J]. Horm Metab Res, 2016, 48(12):795-801.
PMID
|
[8] |
Clinical and Laboratory Standards Institute, International Federation of Clinical Chemistry and Laboratory Medicine. and verifying the reference intervals in a clinical laboratory[S]. C28-A3,CLSI, 2012.
|
[9] |
BALOCH Z, CARAYON P, CONTE-DEVOLX B, et al. Laboratory medicine practice guidelines. Laboratory support for the diagnosis and monitoring of thyroid disease[J]. Thyroid, 2003, 13(1):3-126.
DOI
PMID
|
[10] |
周齐洋, 黄建荣, 陈祥, 等. 血清淀粉样蛋白A化学发光免疫检测技术开发[J]. 生物学杂志, 2019, 36(4):85-88.
|
[11] |
Clinical and Laboratory Standards Institute. Evaluation of detection capability for clinical laboratory measurement procedures[S]. EP17-A2,CLSI, 2012.
|
[12] |
Clinical and Laboratory Standards Institute. Evaluation of the linearity of quantitative ensurement procedures[S]. EP06-A,CLSI, 2003.
|
[13] |
Clinical and Laboratory Standards Institute. User verification of precision and estimation of bias[S]. EP05-A3,CLSI, 2015.
|
[14] |
中国合格评定国家认可委员会. CNAS-GL037 临床化学定量检验程序性能验证指南[S]. 北京: 中国合格评定国家认可委员会, 2019.
|
[15] |
中华人民共和国国家卫生和计划生育委员会. WS/T 416—2013 干扰实验指南[S]. 北京: 中国标准出版社, 2013.
|
[16] |
SMITH T J, HEGEDÜS L. Graves' disease[J]. N Engl J Med, 2016, 375(16):1552-1565.
DOI
URL
|
[17] |
谢晓婷, 梁健夫, 莫超云. 促甲状腺激素受体抗体在诊断毒性弥漫性甲状腺肿病中的应用价值[J]. 中国当代医药, 2021, 28(20):187-189.
|
[18] |
TOZZOLI R, BAGNASCO M, GIAVARINA D, et al. TSH receptor autoantibody immunoassay in patients with Graves' disease:improvement of diagnostic accuracy over different generations of methods. Systematic review and meta-analysis[J]. Autoimmun Rev, 2012, 12(2):107-113.
DOI
URL
|
[19] |
BLOOM J N, HERMAN D C, ELIN R J, et al. Intravenous fluorescein interference with clinical laboratory tests[J]. Am J Ophthalmol, 1989, 108(4):375-379.
PMID
|
[20] |
AUTILIO C, MORELLI R, LOCANTORE P, et al. Stimulating TSH receptor autoantibodies immunoassay:analytical evaluation and clinical performance in Graves' disease[J]. Ann Clin Biochem, 2018, 55(1):172-177.
DOI
URL
|
[21] |
KIM J J, JEONG S H, KIM B, et al. Analytical and clinical performance of newly developed immunoassay for detecting thyroid-stimulating immunoglobulin,the Immulite TSI assay[J]. Scand J Clin Lab Invest, 2019, 79(6):443-448.
DOI
URL
|
[22] |
HU Y, NI J, CEN Y, et al. Evaluation of analytic and clinical performance of two immunoassays for detecting thyroid-stimulating receptor antibody in the diagnosis of Graves' disease[J]. J Clin Lab Anal, 2021, 35(12):e23950.
DOI
URL
|